A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated …

E Robenshtok, RK Grewal, S Fish, M Sabra, RM Tuttle - Thyroid, 2013 - liebertpub.com
Background: Postsurgical thyrotropin (TSH)-stimulated serum thyroglobulin (Tg) level can be
used to predict the likelihood of finding radioactive iodine (RAI) avid metastatic foci on …

[HTML][HTML] Long-term prognostic value of the response to therapy assessed by laboratory and imaging findings in patients with differentiated thyroid cancer

M Klain, E Zampella, L Piscopo, F Volpe, M Manganelli… - Cancers, 2021 - mdpi.com
Simple Summary In patients with differentiated thyroid cancer (DTC), the American Thyroid
Association dynamic risk stratification system has been proposed to identify patients at …

Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective …

SY Kwon, SW Lee, EJ Kong, K Kim, BI Kim… - European Journal of …, 2020 - Springer
Purpose We investigated whether predictive clinicopathologic factors can be affected by
different response criteria and how the clinical usefulness of radioactive iodine (RAI) therapy …

[HTML][HTML] Thyroglobulin value predict iodine-123 imaging result in differentiated thyroid cancer patients

A Campennì, RM Ruggeri, M Siracusa, D Romano… - Cancers, 2023 - mdpi.com
Simple Summary This study was prompted to assess the diagnostic performance of 123I-Dx-
WBS-SPECT/CT in the identification of incomplete structural response in the early follow-up …

[HTML][HTML] Differentiated thyroid cancer outcomes after surgery and activity-adjusted 131I theragnostics

AM Avram, N Rosculet, NH Esfandiari… - Clinical nuclear …, 2019 - journals.lww.com
Purpose The aim of this study was to determine clinical outcomes in patients with
differentiated thyroid cancer after surgery and activity-adjusted 131 I therapy informed by …

[HTML][HTML] Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan

M Chao - Clinical Oncology, 2010 - Elsevier
BACKGROUND: Differentiated thyroid carcinoma (DTC) with rising thyroglobulin (Tg) level
and negative radioiodine whole body scan results has been observed in follow-up studies …

Avidity and outcomes of radioiodine therapy for distant metastasis of distinct types of differentiated thyroid cancer

J Simões-Pereira, N Mourinho… - The Journal of …, 2021 - academic.oup.com
Context The recommendations for radioactive-iodine treatment (RAIT) in metastatic
differentiated thyroid cancer (DTC) are mostly based in the experience with papillary …

Intermediate‐risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long‐term outcome study

S Ballal, R Soundararajan, A Garg… - Clinical …, 2016 - Wiley Online Library
Objective The mute question is whether patients with DTC of intermediate risk of recurrence,
second most common presentation, who were surgically ablated in the first place, ever …

[HTML][HTML] Prognostic Impact of Direct 131I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A …

JF Carrillo, R Vázquez-Romo… - Frontiers in …, 2019 - frontiersin.org
Background: Patients treated for intermediate-or high-risk differentiated thyroid carcinoma
(DTC) and Thyroglobulin (TG) elevation during follow-up, require a diagnostic whole-body …

Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer

D Albano, M Bonacina, R Durmo, F Bertagna… - Endocrine, 2020 - Springer
Purpose The aim of our study was to compare the efficacy of thyroid remnant ablation using
low (1.1 GBq) and intermediate-high radioiodine (RAI) activity (1.85–3.7 GBq) in low-risk …